-+ 0.00%
-+ 0.00%
-+ 0.00%

Insulet publishes investor presentation outlining Omnipod growth strategy and product pipeline

PUBT·08/05/2026 11:26:01
Listen to the news
Insulet publishes investor presentation outlining Omnipod growth strategy and product pipeline
  • Insulet outlined growth plans around Omnipod 5 expansion, a next-generation Omnipod 6 platform, and a fully closed-loop system for type 2 diabetes.
  • Reported 2025 revenue of USD 2.7 billion, more than 600,000 active customers, and presence in 26 global markets.
  • Targets U.S. type 1 diabetes penetration of 50%-55% by 2028 from about 40% today; targets U.S. type 2 diabetes penetration of 10%-15% from about 5%.
  • Pipeline milestones include Omnipod 6 clinical study results with a 510(k) filing, then launch; type 2 fully closed-loop pivotal study start, 510(k) filing, then launch.
  • Highlighted 2021-2025 financial trajectory, including adjusted operating margin rising to 17.6% and free cash flow of USD 378 million in 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insulet Corporation published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.